bovnews1d
AbbVie Inc (ABBV) Reported a 30.61% Operating Margin Last Year—What’s the Real Story?
AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.5 which represents a decrease of $-1.03 or -0.57% from the prior close of $179.53. The stock opened at $179.2 and touched a low of $176.18 ...
Abbvie to record $3.5 bln charge related to schizophrenia drug
Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...
AbbVie’s Strategic Acquisition and Long-Term Growth Potential Justify Buy Rating Despite Short-Term EPS Adjustments
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 6. Analyst David Risinger ...
AbbVie sees $3.5B impairment charge related to emraclidine
In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the ...
Leerink Partnrs Issues Negative Forecast for AbbVie Earnings
Investment analysts at Leerink Partnrs dropped their FY2024 EPS estimates for AbbVie in a research note issued to investors ...
AbbVie's Stock Is Unfairly Cheap
The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...
FierceBiotech1d
AbbVie takes $3.5B hit after emraclidine's phase 2 flop in schizophrenia
The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...
Leerink Partnrs Forecasts AbbVie FY2029 Earnings
Stock analysts at Leerink Partnrs issued their FY2029 EPS estimates for AbbVie in a research report issued on Monday, January ...
AbbVie Inc. stock underperforms Tuesday when compared to competitors
This was the stock's second consecutive day of losses.
AbbVie Inc. (NYSE:ABBV) is largely controlled by institutional shareholders who own 73% of the company
If you want to know who really controls AbbVie Inc. ( NYSE:ABBV ), then you'll have to look at the makeup of its share ...